VALETTE ethinyloestradiol / dienogest tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

valette ethinyloestradiol / dienogest tablet blister pack

bayer australia ltd - dienogest, quantity: 2 mg; ethinylestradiol, quantity: 0.03 mg - tablet, sugar coated - excipient ingredients: calcium carbonate; ferric oxide; macrogol 6000; glycol montanate; glycerol; sucrose; lactose monohydrate; maize starch; povidone; titanium dioxide; purified talc; magnesium stearate - valette is indicated for use as an oral contraceptive and in the treatment of mild to moderate acne in women who seek oral contraception.

Lisa 2 mg/0.03 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

lisa 2 mg/0.03 mg film-coated tablets

laboratorios leon farma, s.a. - dienogest; ethinylestradiol - film-coated tablet - 2.0 mg/0.03 milligram(s) - progestogens and estrogens, fixed combinations; dienogest and estrogen

Ethinylestradiol/Drospirenone Leon Farma & Placebo 0.03 mg/3 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

ethinylestradiol/drospirenone leon farma & placebo 0.03 mg/3 mg film-coated tablets

laboratorios leon farma, s.a. - ethinylestradiol; drospirenone - film-coated tablet - 0.03/3 milligram(s) - progestogens and estrogens, fixed combinations; drospirenone and ethinylestradiol

MICRONELLE 30 ED levonorgestrel 150 microgram and ethinylestradiol 30 microgram film-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

micronelle 30 ed levonorgestrel 150 microgram and ethinylestradiol 30 microgram film-coated tablet blister pack

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; levonorgestrel, quantity: 150 microgram - tablet, film coated - excipient ingredients: povidone; magnesium stearate; lactose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - oral contraception.

Mistra 2mg/0.03mg Film-Coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

mistra 2mg/0.03mg film-coated tablets

gedeon richter plc - dienogest; ethinylestradiol - film-coated tablet - 2mg/0.03 milligram(s) - progestogens and estrogens, fixed combinations; dienogest and ethinylestradiol

Ethinylestradiol/Drospirenon Mylan 0.03 mg - 3 mg tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ethinylestradiol/drospirenon mylan 0.03 mg - 3 mg tabl.

viatris gx bv-srl - ethinylestradiol 0,03 mg; drospirenone 3 mg - tablet - 0,03 mg - 3 mg - ethinylestradiol 0.03 mg; drospirenone 3 mg - drospirenone and ethinylestradiol

Ethinylestradiol/Drospirenon Mylan 0.02 mg - 3 mg tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ethinylestradiol/drospirenon mylan 0.02 mg - 3 mg tabl.

viatris gx bv-srl - ethinylestradiol 0,02 mg; drospirenone 3 mg - tablet - 0,02 mg - 3 mg - ethinylestradiol 0.02 mg; drospirenone 3 mg - drospirenone and ethinylestradiol

YANA drospirenone 3 mg and ethinylestradiol 20 microgram film coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

yana drospirenone 3 mg and ethinylestradiol 20 microgram film coated tablet blister pack

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.